Funding of malaria research by WHO region: 1977–1992 versus 1993–2008.

<p>AFRO, WHO region for Africa; AMRO, WHO region for the Americas; EMRO, WHO region for Eastern Mediterranean; EURO, WHO region for Europe; HQ, WHO Headquarters; SEARO, WHO region for South-East Asia; WPR, WHO region for the Western Pacific.</p

Funding of malaria research by activity: committees 1977–1992 versus task forces 1993–2008.

<p>CHEMAL, Chemotherapy of malaria; FIELDMAL, Epidemiology of malaria; IMMAL, Immunology of malaria; NETs, bednets; ACTs, artemisinin combination therapy; SM, severe malaria; HMM, home management of malaria.</p

TDR Research and Research Capacity Strengthening (RCS) funding, 1975–2008.

<p>TDR Research and Research Capacity Strengthening (RCS) funding, 1975–2008.</p

Variety of disciplines involved in malaria research funded: committees 1977–1992 versus task forces 1993–2008.

<p>Variety of disciplines involved in malaria research funded: committees 1977–1992 versus task forces 1993–2008.</p

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.

<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.</p

Screening and pre-treatment (baseline) characteristics.

<p>Screening and pre-treatment (baseline) characteristics.</p

CONSORT flowchart.

<p>AE–adverse event, FU–follow up, M–Month, LLM—<i>Loa loa</i> microfilaraemia measurement, LFU–Lost to FU, Tx–treatment.</p

<i>M</i>. <i>perstans</i> microfilariae levels in participants in whom <i>M</i>. <i>perstans</i> was detectable at least once during the study by treatment group.

<p>mf per ml: microfilaria per millilitre of blood.</p

Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml.

<p>Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml.</p

Minimum, 25%, 50th, 75th percentile and maximum of the % reduction from pre-treatment values.

<p>P placebo, 2x 2 doses albendazole, 6x 6 doses albendazole, -1 value obtained during screening (4–12 weeks prior to baseline measurement and first treatment), 2, 4, 6, 8, 10, 14, 18, 21, 24 Months after the first treatment at which LLM was measured.</p